Abstract
HER2 is a transmembrane tyrosine kinase receptor in the EGFR (epidermal growth factor receptor) family. The role of HER2 has been most thoroughly studied in breast cancer, in which constitutively active HER2 is overexpressed in 18-22% of cases and is correlated with a poor prognosis. Hence, effective inhibition of the constitutive HER2 signaling in cancer cells has been a major goal in the design of therapies. Therapeutic targeting of HER2 with humanized antibodies such as trastuzumab (Herceptin TM, Genentech) South San Francisco, CA) has proven to be an effective approach for the treatment of breast cancer cells that over-express HER2. The encouraging results of trastuzumab in patients with metastatic and early breast cancer diseases have prompted the evaluation of new HER2 inhibitors for increasing the potential for combinatorial therapies. This review will focus on patents that target HER2 in anti-cancer treatment.
Keywords: HER2, breast cancer, target-therapies
Recent Patents on Anti-Cancer Drug Discovery
Title: Anti-HER2 Treatment and Breast Cancer: State of the Art, Recent Patents, and New Strategies
Volume: 4 Issue: 1
Author(s): Lorenzo Daniele and Anna Sapino
Affiliation:
Keywords: HER2, breast cancer, target-therapies
Abstract: HER2 is a transmembrane tyrosine kinase receptor in the EGFR (epidermal growth factor receptor) family. The role of HER2 has been most thoroughly studied in breast cancer, in which constitutively active HER2 is overexpressed in 18-22% of cases and is correlated with a poor prognosis. Hence, effective inhibition of the constitutive HER2 signaling in cancer cells has been a major goal in the design of therapies. Therapeutic targeting of HER2 with humanized antibodies such as trastuzumab (Herceptin TM, Genentech) South San Francisco, CA) has proven to be an effective approach for the treatment of breast cancer cells that over-express HER2. The encouraging results of trastuzumab in patients with metastatic and early breast cancer diseases have prompted the evaluation of new HER2 inhibitors for increasing the potential for combinatorial therapies. This review will focus on patents that target HER2 in anti-cancer treatment.
Export Options
About this article
Cite this article as:
Daniele Lorenzo and Sapino Anna, Anti-HER2 Treatment and Breast Cancer: State of the Art, Recent Patents, and New Strategies, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (1) . https://dx.doi.org/10.2174/157489209787002489
DOI https://dx.doi.org/10.2174/157489209787002489 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
Current Cancer Drug Targets Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology Pharmacogenetics of Obesity Drug Therapy
Current Molecular Medicine GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Development of In Vitro Co-Culture Model in Anti-Cancer Drug Development Cascade
Combinatorial Chemistry & High Throughput Screening Comparative Study of Encoder-decoder-based Convolutional Neural Networks in Cartilage Delineation from Knee Magnetic Resonance Images
Current Medical Imaging Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry Are Anti-Angiogenic Drugs Useful in Neurodegenerative Disorders?
CNS & Neurological Disorders - Drug Targets Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Effective Inhibition of Foam Cells Formation by Tanshinone IIA in RAW264.7 Macrophages Induced with LDL Isolated from Hypercholesterolemia Patients: A Proteomic Analysis
Current Proteomics Polymorphisms in TOLL-Like Receptor Genes and their Roles in Allergic Asthma and Atopy
Recent Patents on Inflammation & Allergy Drug Discovery An In Silico Appraisal of Azoic and Disulphide Derivatives for Anticancer Activity Against HPV E6 Oncoprotein to Medicate Cervical Cancer
Combinatorial Chemistry & High Throughput Screening Targeting Metallothionein for Prognosis and Treatment of Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery Meet Our Regional Editor
Anti-Cancer Agents in Medicinal Chemistry The Yin and Yang of CD4+ Regulatory T Cells in Autoimmunity and Cancer
Current Medicinal Chemistry BRCA1 as Target for Breast Cancer Prevention and Therapy
Anti-Cancer Agents in Medicinal Chemistry Mesothelioma - Update on Management
Current Respiratory Medicine Reviews Bisacylimidoselenocarbamates Cause G2/M Arrest Associated with the Modulation of CDK1 and Chk2 in Human Breast Cancer MCF-7 Cells
Current Medicinal Chemistry Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Present Scenario of M-Cell Targeting Ligands for Oral Mucosal Immunization
Current Drug Targets